Sa1052 Fibrosis Progression in Nonalcoholic Fatty Liver Versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies
暂无分享,去创建一个
[1] R. Loomba,et al. Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet , 2014, Alimentary pharmacology & therapeutics.
[2] Rohit Loomba,et al. The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.
[3] A. Wree,et al. From NAFLD to NASH to cirrhosis—new insights into disease mechanisms , 2013, Nature Reviews Gastroenterology &Hepatology.
[4] B. Neuschwander‐Tetri,et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients , 2013, Hepatology.
[5] P. Bedossa,et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.
[6] G. Targher,et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[7] Z. Kutalik,et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. , 2012, Gastroenterology.
[8] M. Abraham,et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.
[9] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[10] S. Friedman,et al. A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis , 2011, Hepatology.
[11] J. Ioannidis,et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.
[12] R. Green,et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. , 2011, Annals of hepatology.
[13] D. O'Connor,et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. , 2010, Gastroenterology.
[14] Scott Harmsen,et al. Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study , 2010, The American Journal of Gastroenterology.
[15] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[16] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[17] P. Giral,et al. Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.
[18] Greger Lindberg,et al. Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.
[19] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[20] S. Sanderson,et al. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial , 2009, Hepatology.
[21] S. Kaneko,et al. Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients , 2009, Diabetes Care.
[22] S. Caldwell,et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.
[23] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[24] S. Caldwell,et al. Thiazolidinediones for the Treatment in NASH: Sustained Benefit After Drug Discontinuation? , 2009, Journal of clinical gastroenterology.
[25] W. Coyle,et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.
[26] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] D. Kleiner,et al. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] G. Aithal,et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.
[29] B. Neuschwander‐Tetri,et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.
[30] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[31] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[32] Olivia T. Abar,et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. , 2006, Gastroenterology.
[33] J. Sung,et al. Histological progression of non‐alcoholic fatty liver disease in Chinese patients , 2005, Alimentary pharmacology & therapeutics.
[34] E. Fassio,et al. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.
[35] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[36] R. N. Macsween,et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? , 2002, Journal of clinical pathology.
[37] Z. Goodman,et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.
[38] M. Rugge,et al. Progression of fibrosis in chronic hepatitis C in children , 2001 .
[39] P. Giral,et al. Liver fibrosis in overweight patients. , 2000, Gastroenterology.
[40] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[41] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[42] J P Vandenbroucke,et al. Bias in meta-analysis detected by a simple, graphical test , 1998 .
[43] M. Bennett,et al. The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.
[44] P. Easterbrook,et al. Publication bias in clinical research , 1991, The Lancet.
[45] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[46] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[47] H. Schünemann,et al. [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[48] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[49] J. Hoofnagle,et al. Progression of fibrosis in chronic hepatitis C. , 2003, Gastroenterology.
[50] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.